Isabella Presch/LinkedIn, Ernest Amankwah/LinkedIn
Jul 18, 2026, 16:58
Isabella Presch: Innovative Trial Designs for Rare Pediatric Studies
Isabella Presch, Senior Medical Director Rare diseases, Advanced therapies and Pediatrics at Fortrea, shared a post on LinkedIn:
”Innovative study designs and analyses for rare pediatric studies International Society on Thrombosis and Haemostasis (ISTH)
Ernest Amankwah presented an innovative approach to add data from non randomized patients to the RCT design in rare pediatric conditions.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 03:07Luke McLaughlin: The First Community Article of the Haemophilia Rights Project
-
Sep 5, 2026, 03:00Panagiotis Christoforou: Proud to Contribute to Barts Health’s Leading Role in UK Clinical Trials
-
Sep 5, 2026, 02:51Kassiani Maria Nastouli: Honored to Be Cited in the New ESC Guidelines on the Management of CVD and CKD
-
Sep 5, 2026, 02:44Sedat Gül: Is It Time to Reconsider the 24-Hour Antiplatelet Delay After Thrombolysis?
-
Sep 5, 2026, 02:35Balaji Balagani: Exploring Stable vs Unstable vs Complete Coronary Block
-
Sep 5, 2026, 02:28N. Mariana S. Vasquez: Warm vs Cold Autoimmune Hemolytic Anemia for USMLE/NBME Questions
-
Sep 4, 2026, 22:03Maeve Crowley: Haemophilia Treatment Over the Decades and Hope for the Future
-
Sep 4, 2026, 22:01Lama Skieker: Understanding Thrombocytopenia in Malaria
-
Sep 4, 2026, 22:00Hiten Patel: How an IVC Filter Helps Prevent Pulmonary Embolism